Piper Sandler Remains a Buy on Teva Pharmaceutical (TEVA)
Piper Sandler analyst David Amsellem maintained a Buy rating on Teva Pharmaceutical today and set a price target of $41.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Amsellem is a 5-star analyst with an average return of 8.3% and a 52.91% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as AbbVie, Amgen, and Teva Pharmaceutical.
Currently, the analyst consensus on Teva Pharmaceutical is a Strong Buy with an average price target of $39.57.
Based on Teva Pharmaceutical’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $4.71 billion and a net profit of $480 million. In comparison, last year the company earned a revenue of $4.23 billion and had a GAAP net loss of $217 million
Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TEVA in relation to earlier this year. Last month, Mark Sabag, the EVP, International Markets Commercial of TEVA sold 62,102.00 shares for a total of $1,871,754.28.
Read More on TEVA:
